Big pharma splurged on NOAC events for doctors
The arrival of non-vitamin K antagonist oral anticoagulants (NOACs) on the Australian market triggered a massive spend on doctors’ education by drug manufacturers, researchers say.
The agents consumed more than a quarter of individual companies’ educational event funding between 2011 and 2015, data shows.
Dabigatran (Pradaxa) manufacturer Boehringer Ingelheim spent more than $3 million on NOAC-related events, 38% of its total spending on doctor events.
NOAC events for rivaroxaban (Xarelto) took up 24% of Bayer’s event budget and Bristol Myers Squibb and Pfizer, which